{"title_page": "Malignant pleural effusion", "text_new": "{{Infobox medical condition (new) \n| name            = Malignant pleural effusion \n| image           =  \n| caption         =  \n| \n| pronounce       =  \n| field           =  \n| synonyms        =  \n| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n'''Malignant pleural effusion''' is a condition in which [[cancer]] causes an abnormal amount of fluid to collect between the thin layers of tissue ([[pleura]]) lining the outside of the lung and the wall of the [[chest cavity]].<ref>{{cite web |title=NCI Dictionary of Cancer Terms |url=https://www.cancer.gov/publications/dictionaries/cancer-terms/def/malignant-pleural-effusion?redirect=true |website=NCI |accessdate=21 December 2018|date=2011-02-02 }}</ref> [[Lung cancer]] and [[breast cancer]] account for about 50-65% of malignant pleural effusions.<ref>{{cite journal |vauthors=Hausheer FH, Yarbro JW |title=Diagnosis and Management of Malignant Pleural Effusion| journal=Seminars in Oncology|volume=12| issue=1| pages=54\u201375 | date= March 1985|pmid=2579439}}</ref><ref>{{cite journal |vauthors=Antony VB, Loddenkemper R, Astoul P, etal |title=Management of malignant pleural effusions |journal=Eur. Respir. J. |volume=18 |issue=2 |pages=402\u201319 |date=August 2001 |pmid=11529302 |doi=10.1183/09031936.01.00225601}}</ref>  Other common causes include [[pleural |pleural mesothelioma]] and [[lymphoma]].\n\n==Diagnosis==\n\n===Clinical evaluation===\nClinical factors predicting the diagnosis of malignant pleural effusions are symptoms lasting more than 1 month and the absence of fever.<ref>{{cite journal |vauthors=Ferrer J, Rold\u00e1n J, Teixidor J, Pallisa E, Gich I, Morell F |title=Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy |journal=Chest |volume=127 |issue=3 |pages=1017\u201322 |date=March 2005 |pmid=15764788 |doi=10.1378/chest.127.3.1017 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=15764788}}</ref>\n\n===Imaging===\nThis is needed to confirm the presence of a [[pleural effusion]].  [[Chest radiograph]] is usually performed first and may demonstrate an underlying lung cancer as well as the pleural effusion.  [[Ultrasound]] has a sensitivity of 73% and specificity of 100% at distinguishing malignant pleural effusions from other causes of pleural effusion, based on the presence of visible pleural metastases, pleural thickening greater than 1&nbsp;cm, pleural nodularity, diaphragmatic thickening measuring greater than 7mm and an echogenic swirling pattern visible in the pleural fluid.<ref>{{cite journal |vauthors=Qureshi NR, Rahman NM, Gleeson FV |title=Thoracic ultrasound in the diagnosis of malignant pleural effusion |journal=Thorax |volume=64 |issue=2 |pages=139\u201343 |date=February 2009 |pmid=18852159 |doi=10.1136/thx.2008.100545 }}</ref><ref>{{cite journal |vauthors=Chian CF, Su WL, Soh LH, Yan HC, Perng WC, Wu CP |title=Echogenic swirling pattern as a predictor of malignant pleural effusions in patients with malignancies |journal=Chest |volume=126 |issue=1 |pages=129\u201334 |date=July 2004 |pmid=15249453 |doi=10.1378/chest.126.1.129 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=15249453}}</ref>\n\n===Biochemical analysis===\nMalignant pleural effusions are [[exudates]].  A low pleural fluid pH is associated with poorer survival and reduced pleurodesis efficacy.<ref>{{cite journal |vauthors=Sahn SA, Good JT |title=Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications |journal=Ann. Intern. Med. |volume=108 |issue=3 |pages=345\u20139 |date=March 1988 |pmid=3341671 |doi=10.7326/0003-4819-108-3-345}}</ref><ref>{{cite journal |vauthors=Rodr\u00edguez-Panadero F, L\u00f3pez Mej\u00edas J |title=Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis |journal=Am. Rev. Respir. Dis. |volume=139 |issue=3 |pages=663\u20137 |date=March 1989 |pmid=2923367 |doi=10.1164/ajrccm/139.3.663}}</ref>\n\n===Histopathology===\nPleural fluid cytology is positive in 60% of cases.  However, in the remaining cases, pleural biopsy is required.  Image guided biopsy and thoracoscopy have largely replaced blind biopsy due to their greater sensitivity and safety profile.  CT guided biopsy has a sensitivity of 87% compared to Abrams' needle biopsy, which has a sensitivity of 47%.<ref>{{cite journal |vauthors=Maskell NA, Gleeson FV, Davies RJ |title=Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial |journal=Lancet |volume=361 |issue=9366 |pages=1326\u201330 |date=April 2003 |pmid=12711467 |doi=10.1016/S0140-6736(03)13079-6}}</ref>\n\n===Biomarkers===\nIdentification of pleural fluid biomarkers to distinguish malignant pleural effusions from other causes of exudative effusions would help diagnosis.  Biomarkers that have been shown to be raised in malignant pleural effusions compared to benign disease include vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinases and tumour markers such as carcinoembryonic antigen.<ref>{{cite journal  |vauthors=Sack U, Hoffmann M, Zhao XJ, etal |title=Vascular endothelial growth factor in pleural effusions of different origin |journal=Eur. Respir. J. |volume=25 |issue=4 |pages=600\u20134 |date=April 2005 |pmid=15802331 |doi=10.1183/09031936.05.00037004 }}</ref><ref>{{cite journal |vauthors=Sumi M, Kagohashi K, Satoh H, Ishikawa H, Funayama Y, Sekizawa K |title=Endostatin levels in exudative pleural effusions |journal=Lung |volume=181 |issue=6 |pages=329\u201334 |year=2003 |pmid=14749937 |doi=10.1007/s00408-003-1035-9 }}</ref><ref>{{cite journal |vauthors=Gaspar MJ, De Miguel J, Garc\u00eda D\u00edaz JD, D\u00edez M |title=Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions |journal=Anticancer Res. |volume=28 |issue=5B |pages=2947\u201352 |year=2008 |pmid=19031938 |url=http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=19031938}}</ref><ref>{{cite journal |vauthors=Vatansever S, Gelisgen R, Uzun H, Yurt S, Kosar F |title=Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions |journal=Clin Invest Med |volume=32 |issue=4 |pages=E293\u2013300 |year=2009 |pmid=19640333 |doi=10.25011/cim.v32i4.6621 }}</ref>  Pleural fluid mesothelin has a sensitivity of 71%, greater than that of cytology, and a specificity of 89% for the diagnosis of malignant mesothelioma.<ref>{{cite journal  |vauthors=Davies HE, Sadler RS, Bielsa S, etal |title=Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions |journal=Am. J. Respir. Crit. Care Med. |volume=180 |issue=5 |pages=437\u201344 |date=September 2009 |pmid=19299498 |doi=10.1164/rccm.200811-1729OC }}</ref>\n\n==Treatment==\nThe goal of treatment of malignant pleural effusions is relief of shortness of breath.<ref>{{cite journal | vauthors = Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ | title = Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010 | journal = Thorax | volume = 65 Suppl 2 | issue = Suppl 2 | pages = ii32\u201340 | date = August 2010 | pmid = 20696691 | doi = 10.1136/thx.2010.136994 }}</ref> Occasionally, treatment of the underlying cancer can cause resolution of the effusion.  This may be the case with types of cancer that respond well to chemotherapy, such as [[small cell carcinoma]] or [[lymphoma]]. Simple aspiration of pleural fluid can relieve shortness of breath rapidly but fluid and symptoms will usually recur within a couple of weeks. Drainage should generally be done under ultrasound guidance.<ref name=Fel2018>{{cite journal | vauthors = Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YC, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA | display-authors = 6 | title = Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline | journal = American Journal of Respiratory and Critical Care Medicine | volume = 198 | issue = 7 | pages = 839\u2013849 | date = October 2018 | pmid = 30272503 | doi = 10.1164/rccm.201807-1415ST }}</ref>\n\nFor this reason, more permanent treatments are usually used to prevent fluid recurrence. Standard treatment involves inserting an indwelling plural catheter and [[pleurodesis]].<ref name=Fel2018/> However, this treatment requires an inpatient stay of approximately 2\u20137 days, can be painful and has a significant failure rate. This has led to the development of tunneled pleural catheters (e.g., [[Pleurx Catheter]]s), which allow outpatient treatment of effusions. If an infection due to the catheter occurs, antibiotics are given and the catheter is generally left in.<ref name=Fel2018/>\n\nA Cochrane review concluded tentatively in favour of thoracoscopy to remove the fluid and blow talc into the pleural cavity (talc poudrage) compared to other commonly used methods. <ref>{{cite journal | vauthors = Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N | title = Interventions for the management of malignant pleural effusions: a network meta-analysis | journal = The Cochrane Database of Systematic Reviews | issue = 5 | pages = CD010529 | date = May 2016 | pmid = 27155783 | pmc = 6450218 | doi = 10.1002/14651858.cd010529.pub2 }}</ref>\n\n==References==\n{{reflist}}\n\n{{NCI-cancer-dict}}\n\n== External links ==\n{{Medical resources\n| DiseasesDB      = \n| ICD10           = \n| ICD9            = {{ICD9|511.81}}\n| ICD10CM         = {{ICD10CM|J91.0}}\n}}\n\n{{Respiratory pathology}}\n\n[[Category:Diseases of pleura]]\n", "text_old": "{{Infobox medical condition (new) \n| name            = Malignant pleural effusion \n| image           =  \n| caption         =  \n| \n| pronounce       =  \n| field           =  \n| synonyms        =  \n| symptoms        = \n| complications   = \n| onset           = \n| duration        = \n| types           = \n| causes          = \n| risks           = \n| diagnosis       = \n| differential    = \n| prevention      = \n| treatment       = \n| medication      = \n| prognosis       = \n| frequency       = \n| deaths          = \n}}\n'''Malignant pleural effusion''' is a condition in which [[cancer]] causes an abnormal amount of fluid to collect between the thin layers of tissue ([[pleura]]) lining the outside of the lung and the wall of the [[chest cavity]].<ref>{{cite web |title=NCI Dictionary of Cancer Terms |url=https://www.cancer.gov/publications/dictionaries/cancer-terms/def/malignant-pleural-effusion?redirect=true |website=NCI |accessdate=21 December 2018|date=2011-02-02 }}</ref> [[Lung cancer]] and [[breast cancer]] account for about 50-65% of malignant pleural effusions.<ref>{{cite journal |vauthors=Hausheer FH, Yarbro JW |title=Diagnosis and Management of Malignant Pleural Effusion| journal=Seminars in Oncology|volume=12| issue=1| pages=54\u201375 | date= March 1985|pmid=2579439}}</ref><ref>{{cite journal |vauthors=Antony VB, Loddenkemper R, Astoul P, etal |title=Management of malignant pleural effusions |journal=Eur. Respir. J. |volume=18 |issue=2 |pages=402\u201319 |date=August 2001 |pmid=11529302 |doi=10.1183/09031936.01.00225601}}</ref>  Other common causes include [[pleural |pleural mesothelioma]] and [[lymphoma]].\n\n==Diagnosis==\n\n===Clinical evaluation===\nClinical factors predicting the diagnosis of malignant pleural effusions are symptoms lasting more than 1 month and the absence of fever.<ref>{{cite journal |vauthors=Ferrer J, Rold\u00e1n J, Teixidor J, Pallisa E, Gich I, Morell F |title=Predictors of pleural malignancy in patients with pleural effusion undergoing thoracoscopy |journal=Chest |volume=127 |issue=3 |pages=1017\u201322 |date=March 2005 |pmid=15764788 |doi=10.1378/chest.127.3.1017 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=15764788}}</ref>\n\n===Imaging===\nThis is needed to confirm the presence of a [[pleural effusion]].  [[Chest radiograph]] is usually performed first and may demonstrate an underlying lung cancer as well as the pleural effusion.  [[Ultrasound]] has a sensitivity of 73% and specificity of 100% at distinguishing malignant pleural effusions from other causes of pleural effusion, based on the presence of visible pleural metastases, pleural thickening greater than 1&nbsp;cm, pleural nodularity, diaphragmatic thickening measuring greater than 7mm and an echogenic swirling pattern visible in the pleural fluid.<ref>{{cite journal |vauthors=Qureshi NR, Rahman NM, Gleeson FV |title=Thoracic ultrasound in the diagnosis of malignant pleural effusion |journal=Thorax |volume=64 |issue=2 |pages=139\u201343 |date=February 2009 |pmid=18852159 |doi=10.1136/thx.2008.100545 }}</ref><ref>{{cite journal |vauthors=Chian CF, Su WL, Soh LH, Yan HC, Perng WC, Wu CP |title=Echogenic swirling pattern as a predictor of malignant pleural effusions in patients with malignancies |journal=Chest |volume=126 |issue=1 |pages=129\u201334 |date=July 2004 |pmid=15249453 |doi=10.1378/chest.126.1.129 |url=http://www.chestjournal.org/cgi/pmidlookup?view=long&pmid=15249453}}</ref>\n\n===Biochemical analysis===\nMalignant pleural effusions are [[exudates]].  A low pleural fluid pH is associated with poorer survival and reduced pleurodesis efficacy.<ref>{{cite journal |vauthors=Sahn SA, Good JT |title=Pleural fluid pH in malignant effusions. Diagnostic, prognostic, and therapeutic implications |journal=Ann. Intern. Med. |volume=108 |issue=3 |pages=345\u20139 |date=March 1988 |pmid=3341671 |doi=10.7326/0003-4819-108-3-345}}</ref><ref>{{cite journal |vauthors=Rodr\u00edguez-Panadero F, L\u00f3pez Mej\u00edas J |title=Low glucose and pH levels in malignant pleural effusions. Diagnostic significance and prognostic value in respect to pleurodesis |journal=Am. Rev. Respir. Dis. |volume=139 |issue=3 |pages=663\u20137 |date=March 1989 |pmid=2923367 |doi=10.1164/ajrccm/139.3.663}}</ref>\n\n===Histopathology===\nPleural fluid cytology is positive in 60% of cases.  However, in the remaining cases, pleural biopsy is required.  Image guided biopsy and thoracoscopy have largely replaced blind biopsy due to their greater sensitivity and safety profile.  CT guided biopsy has a sensitivity of 87% compared to Abrams' needle biopsy, which has a sensitivity of 47%.<ref>{{cite journal |vauthors=Maskell NA, Gleeson FV, Davies RJ |title=Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial |journal=Lancet |volume=361 |issue=9366 |pages=1326\u201330 |date=April 2003 |pmid=12711467 |doi=10.1016/S0140-6736(03)13079-6}}</ref>\n\n===Biomarkers===\nIdentification of pleural fluid biomarkers to distinguish malignant pleural effusions from other causes of exudative effusions would help diagnosis.  Biomarkers that have been shown to be raised in malignant pleural effusions compared to benign disease include vascular endothelial growth factor (VEGF), endostatin, matrix metalloproteinases and tumour markers such as carcinoembryonic antigen.<ref>{{cite journal  |vauthors=Sack U, Hoffmann M, Zhao XJ, etal |title=Vascular endothelial growth factor in pleural effusions of different origin |journal=Eur. Respir. J. |volume=25 |issue=4 |pages=600\u20134 |date=April 2005 |pmid=15802331 |doi=10.1183/09031936.05.00037004 }}</ref><ref>{{cite journal |vauthors=Sumi M, Kagohashi K, Satoh H, Ishikawa H, Funayama Y, Sekizawa K |title=Endostatin levels in exudative pleural effusions |journal=Lung |volume=181 |issue=6 |pages=329\u201334 |year=2003 |pmid=14749937 |doi=10.1007/s00408-003-1035-9 }}</ref><ref>{{cite journal |vauthors=Gaspar MJ, De Miguel J, Garc\u00eda D\u00edaz JD, D\u00edez M |title=Clinical utility of a combination of tumour markers in the diagnosis of malignant pleural effusions |journal=Anticancer Res. |volume=28 |issue=5B |pages=2947\u201352 |year=2008 |pmid=19031938 |url=http://ar.iiarjournals.org/cgi/pmidlookup?view=long&pmid=19031938}}</ref><ref>{{cite journal |vauthors=Vatansever S, Gelisgen R, Uzun H, Yurt S, Kosar F |title=Potential role of matrix metalloproteinase-2,-9 and tissue inhibitors of metalloproteinase-1,-2 in exudative pleural effusions |journal=Clin Invest Med |volume=32 |issue=4 |pages=E293\u2013300 |year=2009 |pmid=19640333 |doi=10.25011/cim.v32i4.6621 }}</ref>  Pleural fluid mesothelin has a sensitivity of 71%, greater than that of cytology, and a specificity of 89% for the diagnosis of malignant mesothelioma.<ref>{{cite journal  |vauthors=Davies HE, Sadler RS, Bielsa S, etal |title=Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions |journal=Am. J. Respir. Crit. Care Med. |volume=180 |issue=5 |pages=437\u201344 |date=September 2009 |pmid=19299498 |doi=10.1164/rccm.200811-1729OC }}</ref>\n\n==Treatment==\nThe goal of treatment of malignant pleural effusions is relief of shortness of breath.<ref>{{cite journal | vauthors = Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ | title = Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010 | journal = Thorax | volume = 65 Suppl 2 | issue = Suppl 2 | pages = ii32\u201340 | date = August 2010 | pmid = 20696691 | doi = 10.1136/thx.2010.136994 }}</ref> Occasionally, treatment of the underlying cancer can cause resolution of the effusion.  This may be the case with types of cancer that respond well to chemotherapy, such as [[small cell carcinoma]] or [[lymphoma]]. Simple aspiration of pleural fluid can relieve shortness of breath rapidly but fluid and symptoms will usually recur within a couple of weeks. Drainage should generally be done under ultrasound guidance.<ref name=Fel2018>{{cite journal | vauthors = Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YC, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA | display-authors = 6 | title = Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline | journal = American Journal of Respiratory and Critical Care Medicine | volume = 198 | issue = 7 | pages = 839\u2013849 | date = October 2018 | pmid = 30272503 | doi = 10.1164/rccm.201807-1415ST }}</ref>\n\nFor this reason, more permanent treatments are usually used to prevent fluid recurrence. Standard treatment involves inserting an indwelling plural catheter and [[pleurodesis]].<ref name=Fel2018/> However, this treatment requires an inpatient stay of approximately 2\u20137 days, can be painful and has a significant failure rate. This has led to the development of tunneled pleural catheters (e.g., [[Pleurx Catheter]]s), which allow outpatient treatment of effusions. If an infection due to the catheter occurs, antibiotics are given and the catheter is generally left in.<ref name=Fel2018/>\n\nA Cochrane review concluded tentatively in favour of thoracoscopy to remove the fluid and blow talc into the pleural cavity (talc poudrage) compared to other commonly used methods. <ref>{{cite journal | vauthors = Clive AO, Jones HE, Bhatnagar R, Preston NJ, Maskell N | title = Interventions for the management of malignant pleural effusions: a network meta-analysis | journal = The Cochrane Database of Systematic Reviews | issue = 5 | pages = CD010529 | date = May 2016 | pmid = 27155783 | pmc = 6450218 | doi = 10.1002/14651858.cd010529.pub2 }}</ref>\n\n==References==\n{{reflist}}\n\n{{NCI-cancer-dict}}\n\n== External links ==\n{{Medical resources\n|   DiseasesDB     = \n|   ICD10          = \n|   ICD9           = {{ICD9|511.81}} \n}}\n\n{{Respiratory pathology}}\n\n[[Category:Diseases of pleura]]\n", "name_user": "Dismanet", "label": "safe", "comment": "Adding new medical resources.", "url_page": "//en.wikipedia.org/wiki/Malignant_pleural_effusion"}
